This is an injectable drug that is already used in patients with diabetes mellitus. It has been registered with Anmat under the name Wegovy and has the same formula as Ozempic intended for people with type 2 diabetes.
The injectable slimming drug will be sold in Argentina. This is Wegovy, a drug similar to Ozempic indicated in the country for patients with type 2 diabetes, which is already registered with the National Drug, Food and Health Technology Administration, according to official sources, confirmed Clarion.
“The registered drug is Wegovy (IFA semaglutide),” a source at Anmat said.
The abbreviation IFA stands for Active Pharmaceutical Ingredients. “This is the same IFA as Ozempic,” they added to the question Clarion.
The drug has gained popularity in recent years because it has been used by celebrities all over the world for quick weight loss. Among them are Elon Musk, Kim Kardashian and Lady Gaga.
In the United States, the Food and Drug Administration (FDA) first approved this injectable for diabetes in 2017; The agency approved a drug with a higher dose of Ozempic’s active ingredient called semaglutide for the treatment of obesity in 2021 under the brand name Wegovy.
This medicine is a version of the drug semaglutide used to control diabetes. According to a statement from a Danish laboratory new nordiskmedicine “listed as diet and exercise supplement for chronic weight control in obese or overweight adults with at least one weight-related comorbidity.
In company-funded studies, participants who took Wegovy reported an average weight loss of 15%, or about 30 pounds. Participants steadily lost weight for 14 months before stabilization.
In the placebo injection comparison group, the average weight loss was about 2.5%, or just under 6 pounds.
“Despite all weight loss efforts, many obese people struggle to achieve and maintain weight loss due to the physiological responses that promote weight gain,” said Martin Holst Lange, executive vice president of development at new nordisk.
Vegovi Side Effects
The most common side effects of Wegovy were gastrointestinal problems, including nausea, diarrhea and vomiting. These effects often disappeared, but about 5% of study participants still they stopped taking it as a consequence of them.
The drug carries a potential risk that the patient will develop a type thyroid tumorTherefore, it should not be used in people with a personal or family history of certain thyroid and endocrine tumors. Wegovy can also generate depression and inflammation of the pancreas.
Wegovy is a synthesized version of an intestinal hormone that reduces appetite. Patients should apply subcutaneous injection weekly.